




Strnadel, J. et al. (2018) Survival of syngeneic and allogeneic iPSC–derived 
neural precursors after spinal grafting in minipigs. Science Translational 
Medicine, 10(440), eaam6651. (doi:10.1126/scitranslmed.aam6651)  
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/162268/             











Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
Survival of syngeneic and allogeneic iPSCs-derived neural precursors after spinal 
grafting in minipigs. 
 
1,2Jan Strnadel, 3Cassiano Carromeu, 4,5Cedric Bardy, 1Michael Navarro,  1Oleksandr 
Platoshyn, 1Andreas N. Glud,  1Silvia Marsala, 1Jozef Kafka, 1,6Atsushi Miyanohara, 7 
Tomohisa Kato Jr., 1Takahiro Tadokoro, 1Michael Hefferan,  1Kota Kamizato, 1Tetsuya 
Yoshizumi,  8 Stefan Juhas, 8Jana Juhasova, 9Chak-Sum  Ho, 9Taba Kheradmand,  1PeiXi 
Chen,  1,10Dasa Bohaciakova, 1,11Marian Hruska-Plochan,  12Andrew J. Todd, 13Shawn P. 
Driscoll, 13Thomas D. Glenn, 13Samuel L. Pfaff , 8Jiri Klima,  14Joseph Ciacci, 14Eric Curtis, 
4Fred H. Gage, 15Jack Bui, 16Kazuhiko Yamada,  3Alysson Muotri,  1,17Martin Marsala 
 
1 Neuroregeneration Laboratory, Department of Anesthesiology, 
University of California-San Diego (UCSD), La Jolla, CA, 92037, USA; 
2 Biomedical Center Martin, Department of Molecular Medicine, Jessenius Faculty of Medicine in 
Martin, Comenius University in Bratislava, 03601 Martin, Slovakia; 
3 Department of Pediatrics, UCSD; 
4 Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, 92037, USA; 
5 Laboratory for Human Neurophysiology and Genetics, SAHMRI Mind and Brain, Australia; 
6 Vector Core Laboratory, UCSD; 
7 Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan; 
8 Institute of Animal Physiology and Genetics, v.v.i., AS CR, Liběchov, Czech Republic;  
9 Histocompatibility Laboratory, Gift of Life Michigan, Ann Arbor, MI, 48108, USA; 
10 Department of Histology and Embryology, Masaryk University, Brno, Czech Republic; 
11Institute of Molecular Life Sciences, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, 
Switzerland; 
12 Institute of Neuroscience and Psychology, College of Medical, 
Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK; 
13 Gene Expression Laboratory and the Howard Hughes Medical Institute, Salk Institute for 
Biological Studies, La Jolla, CA, 92037, USA; 
14 Department of Neurosurgery, UCSD; 
15 Department of Pathology, UCSD; 
16 Columbia University Medical Center Campus, NY, 10032, USA; 
17 Institute of Neurobiology, Slovak Academy Of Sciences, Kosice, Slovakia 
 
One sentence summary: Syngeneic iPSCs-derived neurons survive and mature without 
immunosuppression after grafting into spinal cord of adult pig. 
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Abstract 
The use of autologous (or syngeneic) cells derived from induced pluripotent stem cells 
(iPSCs) holds great promise for future clinical use in a wide range of diseases and injuries. It is 
expected that cell replacement therapies using autologous cells would forego the need for 
immunosuppression, otherwise required in allogeneic transplantations. However, recent studies have 
shown the unexpected immune-rejection of undifferentiated autologous mouse iPSCs after 
transplantation. Whether similar immunogenic properties are maintained in iPSCs-derived lineage-
committed cells (such as neural precursors) is relatively unknown. Here we demonstrate that 
syngeneic porcine iPSCs-derived neural precursor cells (NPCs) transplantation to the spinal cord in 
absence of immunosuppression is associated with long-term survival and neuronal and glial 
differentiation. No tumor formation was noted. Similar cell engraftment and differentiation was 
shown in spinally-injured transiently immunosuppressed swine leukocyte antigen (SLA)-
mismatched allogeneic pigs. These data demonstrate that iPSCs-derived NPCs can be grafted into 
syngeneic recipients in the absence of immunosuppression and that temporary immunosuppression 
is sufficient to induce long-term immune tolerance after NPCs engraftment into spinally-injured 
allogeneic recipients. Collectively, our results show that iPSCs-NPCs represent an alternative source 
of transplantable NPCs for the treatment of a variety of disorders affecting the spinal cord including 
















The technology for generating iPSCs (1, 2) has opened new possibilities for patient-specific 
cell therapy, in vitro disease modeling and drug discovery. Although disease-specific iPSCs 
provide an excellent tool for studying the developmental pathology of human diseases in vitro (3, 
4), the use of iPSCs for spinal cord autologous, syngeneic or allogeneic transplantation has never 
been tested in large animal models. The use of  large animal models that show similarities in spinal 
cord and CNS anatomy and function with humans are necessary for advancing cell transplantation 
therapies using iPSCs technology to a clinical setting.  
Given the ethical issues related to the use of primates, pigs serve as an alternative model 
for preclinical experiments in regenerative medicine (5, 6). However, isolation of embryonic stem 
cells (ESCs) from pigs is difficult and not effective (7). Several groups reported successful 
generation of pig iPSCs, but the engraftment properties of autologous or syngeneic iPSCs-derived 
neural precursors once grafted back into CNS were rarely  explored (8-11). Therefore, we sought 
to test the immunogenicity and engraftment properties of iPSCs-derived lineage-committed NPCs, 
which are expected to be free of pluripotent cell contaminants and therefore not form teratoma-
like tumor masses.  
Here, we analyze syngeneic transplantations of pig NPCs derived from SLA-inbred pig 
iPSCs. NPCs were isolated by manual clone selection, expanded and characterized before 
transplantation. Three months after transplantation into the spinal cord of syngeneic recipients in 
the absence of immunosuppression, NPCs showed robust engraftment and neuronal/glial 
differentiation without detectable rejection or tumor formation. In addition, a comparable degree 
of cell engraftment and differentiation was observed after allogeneic transplant in transiently 
immunosuppressed pigs with previous chronic spinal traumatic injury. No detectable presence of 
circulating anti-iPSCs-NPCs antibodies was seen in iPSCs-NPCs-grafted non-immunosuppressed 
syngeneic or transiently-immunosuppressed allogeneic pigs. 
These data demonstrate the lack of immunogenicity of iPSCs-NPCs engrafted into naive 
non-injured or spinal trauma-injured spinal cord. In addition, the successful engraftment observed 
in allogeneic animals receiving only time-limited immunosuppression indicates a potential for 
clinical utilization of human iPSCs-derived NPCs in patients with a different human leukocyte 




NPCs derived from reprogrammed adult porcine skin fibroblasts generate functional 
neurons in vitro 
We first generated the porcine iPSCs-derived NPCs. Four fully SLA-matched adult pigs were 
used to obtain skin biopsies (Fig. 1A). All tissue explants successfully produced fibroblasts (Fig. 
1B)  and pluripotent colonies (Fig. 1 C, D ) after reprogramming using Sendai vectors (12) encoding 
octamer-binding transcription factor 4 (OCT4), (sex determining region Y)-box 2 (SOX2), Kruppel-
like factor 4 (KLF4) and myelocytomatosis viral oncogene (c-MYC). Expression of the pluripotent 
markers such as KLF4, SOX2, OCT4 and Nanog homeobox (NANOG) was seen in proliferating 
iPSCs colonies (Fig. 1 E-H). Previously frozen iPSCs (passage 12-18) showed a comparable 
formation of pluripotent colonies and expression of pluripotent markers (fig. S1 A-F).  
To test the differentiation potential of established iPSCs three different in vitro or in vivo 
assays were used. First, proliferating colonies were induced to form embryoid bodies (EBs) (Fig. 
1I) and continuously cultured in the presence of pig serum (0.1-1%) for 3-4 weeks. Second, a single 
monolayer of iPSCs was induced using established germ layer-specific (ectoderm, endoderm or 
mesoderm) induction protocols for 10-14 days. After induction, EBs and induced iPSCs were stained 
with markers of mesoderm [smooth muscle actin-SMA, Brachyury), endoderm (alpha-fetoprotein 
(AFP), sex determining region Y (SOX17)] and ectoderm [orthodenticle homeobox 2 (OTX2), 
neuron-specific Class III β-tubulin (TUJ1)]. Third, a single cell suspension of iPSCs was injected 
into the testes of immunodeficient mice and the presence of teratomas analyzed at 4-8 weeks after 
injection. Staining of in vitro-induced EBs (fig. S1 G-J) or induced single cell-seeded iPSCs (fig. 
S1 K-M) shows the expression of definitive ectoderm, endoderm and mesoderm markers. 
Macroscopic inspection of iPSCs-injected testes showed extensive bilateral tumor formation at 
intervals longer than 5 weeks after cell injection (fig. S1 N-left bottom black-background inset). 
H&E staining of histological sections taken from injected testes showed developed teratomas with 
all 3 germ layer derivatives (Fig. 1J and fig. S 1N). 
To generate NPCs, EBs were cultured in the presence of basic fibroblast growth factor 
(bFGF) to potentiate the formation of neural rosettes (Fig. 1K). Neural precursor cells were then 
manually harvested from the periphery of neural rosettes. NPCs were further expanded with bFGF 
as a sole mitogen (10 ng/mg) for up to 35 passages (Fig. 1 L) with expression of neural precursor 
markers including SOX2, type VI intermediate filament protein (NESTIN), aniridia type II protein 
(PAX6) and SRY-box 1 (SOX1) (Fig. 1 M-P). Comparable neural precursor morphology in 
previously frozen and re-plated NPCs (passage 24) was also seen (fig. S 2, A and B). Karyotype 
analysis using Giemsa banding (G-banding) demonstrated a stable karyotype in proliferating NPCs 
at passage 15 and 30 (fig. S2, C and D). Quantitative flow cytometry analysis showed 91±14% of 
SOX1+ cells, 51.7±12% of PAX6+, 90.8±9% of SOX2+ and 72.3±17% of NESTIN+ cells, 
respectively (fig. S2 E-J).  
To characterize the multi-lineage potential of our iPSC-derived NPCs, we subcultured NPCs 
on an established human fetal astrocyte monolayer and then induced by withdrawal of bFGF and 
addition of cyclic adenosine monophosphate (cAMP), brain-derived neurotrophic factor (BDNF) 
and glial cell-derived neurotrophic factor (GDNF). The cultured NPCs were designed to express 
Enhanced Green Fluorescent Protein (EGFP) under the synapsin (SYN) promoter, and 
immunofluorescence staining of 8 weeks-induced NPCs showed multipolar EGFP+ neurons 
expressing doublecortin (DCX) and Fox-3 (NeuN) (Fig. 1, R and S). A subpopulation of DCX+ 
neurons showed gamma-aminobutyric acid (GABA) immunoreactivity (Fig. 1T). TUJ1 
immunoreactivity was also seen (Fig. 1U). To assess the functionality of induced neurons in vitro, 
we measured spontaneous oscillation in cytosolic calcium (Ca2+) after loading the induced neurons 
with the Ca2+ indicator dye Fluo-4 AM. A consistent cyclical-type of calcium oscillation lasting 
between 4.0-17.6 seconds, suggestive of neuronal depolarization, was observed in numerous neurons 
(Fig. 1V-white boxed regions). To characterize quantitatively the number of neuronal and glial cells 
that can be induced from iPSCs-NPCs, proliferating NPCs were treated with 1% porcine serum for 
20 days. Qualitative and quantitative analysis of induced NPCs showed effective differentiation to 
neurons (expressing the neuronal marker TUJ1), astrocytes [expressing the astrocyte marker glial 
fibrillary acidic protein (GFAP)] and glial and oligodendrocytes/precursors [(expressing 
VIMENTIN, chondroitin sulphate proteoglycan 4 (NG2) and oligodendrocyte transcription factor 
(OLIG2)], (fig. S 2K-N). 
 
In vivo transplanted  iPSCs-NPCs generate functional neurons  at 7-10 months after 
grafting into striata of immunodeficient rats  
We next tested the functionality of porcine iPSCs- derived NPCs (SYN-EGFP-NPCs) after 
grafting into the striatum of adult immunodeficient rats (Fig. 2A). Animals (n=12) received 3 
bilateral injections of SYN-EGFP-NPCs (30,000 cells/injection; 2 µl/injection site) into the 
striatum. One to ten months after cell grafting, we prepared ex vivo brain slices and performed 
patch clamp recordings from SYN-EGFP+ grafted cells (Fig. 2B; fig. S3A). A subset (n=6) of 
grafted animals was perfused with cold saline and striata harvested for mRNA sequencing (to 
analyze porcine-specific transcripts), (n=2; two individual NPCs-grafted striata analyzed at 10 
months post-grafting) or fixed with 4% paraformaldehyde (n=4; 7 months after grafting) and the 
grafted cells studied with immunofluorescence staining with neuron specific antibodies (NeuN, 
neuron-specific enolase (NSE), DCX, SYN, vesicular GABA transporter (VGAT), gephyrin, 
neurofilament (NF)). A relative number (% of total EGFP+ neurons) of double-immunoreactive 
EGFP/DCX, EGFP/NeuN and EGFP/NSE neurons was quantified using confocal microscope  
(Table S 1).  
Patch clamp recording in EGFP+ neurons showed that all the examined transplanted cells 
(n=3) showed properties of mature neurons, such as robust trains of action potentials (average = 
18 Hz) in response to 500 ms depolarizing steps of currents (Fig. 2C), large voltage-gated 
sodium/potassium currents (Nav peak average = -5745 pA) (Fig. 2D), low resting membrane 
potentials (average = -78 mV) and spontaneous excitatory synaptic activity (Table S 2).  
Immunofluorescence staining revealed numerous SYN-EGFP+ neurons with extensive 
processes in the grafted striatal regions (Fig. 2E). Confocal microscopy showed that virtually all 
SYN-EGFP+ cells colocalized with NeuN (Fig. 2E-insets; fig. S, 3 A and B). Similarly, intense 
porcine-specific, neuron-specific enolase (NSE) expression (13) was seen in EGFP+ grafts (Fig. 
2F; fig. S 3C). Staining with antibodies specific for SYN and/or VGAT showed a high density of 
SYN/EGFP+ or SYN/VGAT+ puncta on the soma/membranes of endogenous NeuN positive 
neurons or EGFP+ grafted neurons (Fig. 2, G and H; fig. S 3D). Co-staining with presynaptic 
inhibitory marker (VGAT) and postsynaptic glycine receptor marker (gephyrin) showed the 
presence of glycine receptors on grafted EGFP+ neurons in opposition to VGAT+ terminals (Fig. 
2I; insert) suggesting the development of inhibitory glycin-ergic synaptic contacts. Staining with 
NF antibody showed high density NF neural processes within EGFP+ grafts (fig. S 3E).  
 
Transplanted iPSCs-NPCs are non-tumorigenic and acquire genetic signature of 
mature porcine CNS  at 7-10 months after grafting into striata of immunodeficient rat  
We next performed whole-transcriptome mRNA  sequencing analysis on the striatum of 
immunodeficient rats that had received iPSCs-NPCs grafts (Fig.3 A-D). Striatal tissue was 
harvested 10 months after iPSCs-NPCs grafting. To separate the pig mRNA sequence reads from 
the host rat mRNA reads, we developed a bioinformatics pipeline to sort mRNA sequence reads 
in a species-specific manner to either pigs or rats (Fig.3E). Slight variations in the genome 
sequence between pigs and rats allowed us to differentiate between the species with a high 
sensitivity (99.52% efficiency). We detected 9332 pig genes expressed in the grafted rat striatum. 
This represented 5.19% of the total mRNA reads from the graft tissue, with a false positive sorting 
rate of 0.47% (appendix 1), (Table S 3). Gene expression was analyzed with t-distributed 
stochastic neighbor embedding (t-SNE) to determine the global gene expression patterns in the 
samples. Gene expression patterns from the transplanted iPSCs-NPCs correlated strongly with the 
expression pattern of control mature pig CNS tissue, but  not with the original iPSCs-NPCs or iPS 
cell populations (Fig. 3F). Analysis of mature CNS-specific transcripts in grafted cells shows high 
expression of neuronal markers and only moderate to low expression of glial genes (fig. S, 3F and 
G). These data indicate that transplanted iPSCs-derived NPCs differentiate normally into neuronal 
and glial subtypes, and adopt gene expression patterns indicative of the environment into which 
they were grafted.  
To identify any neuropathologically-defined signs of tumor formation, sections were also 
stained using H&E. Consistent with immunofluorescence staining, well incorporated grafts that 
fused with the host tissue were identified. No gross signs of tissue necrosis or aberrant tissue 
proliferation were noted (fig. S 4A). Staining with myelin basic protein (MBP) and OLIG2 
antibody showed incomplete myelination in EGFP+ grafts which was in contrast with the 
surrounding host tissue (fig. S 4 B-D). In the same areas the presence of VIMENTIN+ cells and 
oligodendrocytes (OLIG2+) was also seen suggesting ongoing myelination (fig. S 4 E-G).  
Staining with endothelial marker Reca-1 showed regularly distributed vessel profiles in 
EGFP+ grafts (fig. S 5, A and B). The expression of a subset of proto-oncogenes and tumor 
suppressor genes in grafted rat striata at 10 months post-grafting was very similar to that observed 
in normal control pig spinal cord and striatum tissue (fig. S 5C).  
Collectively, these data show that we have generated a transplantable, non-tumorigenic 
population of porcine iPSCs-derived NPCs that shows a robust neuronal differentiation and is 
functional once grafted into the adult CNS of immunodeficient rats.  
 
Syngeneic porcine iPSCs-NPCs grafted spinally in adult naive pigs show long-term 
survival in the absence of immunosuppression 
We next tested if the syngeneic transplantation of porcine iPSCs-NPCs into the lumbar 
spinal cord of naive spinally-non-injured pigs would support cell survival in the absence of 
immunosuppression . Three SLA fully-matched minipigs received 20 bilateral syngeneic grafts of 
iPSCs-NPCs (SYN-EGFP+) targeted into the central gray matter of the L2-L5 spinal cord 
segments (50,000 live cells/µl, 10 µl/injection). Three months after grafting the animals were 
sacrificed and the spinal cord harvested for subsequent analysis. 
Immunofluorescence analysis of horizontal spinal cord sections throughout the grafted 
region showed the presence of long bilateral EGFP+ grafts extending for more than 2 cm (Fig. 4A, 
fig. S 6A). No tumor formation or aberrant tissue mass was seen in any animal. High density NF-
positive and GFAP-positive networks were identified in EGFP+ grafts (Fig. 4, B and C; fig. S 6, 
B and C). Staining with neuron-specific markers including DCX, NeuN and NSE showed neurons 
that occupied the entire EGFP+ grafts (Fig. 4 D-F; fig. S 6 D-F). Analysis of axonal projections 
into regions caudal and cranial from the border of the EGFP+ graft showed the projection of 
EGFP+ axons for distances longer than 2-3 cm. These axons showed co-expression of NF (Fig. 4 
G-I). A quantitative analysis (% of total EGFP+ neurons) of double-immunoreactive EGFP/DCX, 
EGFP/NeuN and EGFP/NSE neurons is presented in Table S 1.  
Staining with SYN antibody revealed a high density of SYN+ puncta throughout the 
EGFP+ graft (fig. S 6 G). The majority of EGFP/SYN+ puncta displayed colocalization with 
VGAT and was opposed to a postsynaptic gephyrin+ puncta found on EGFP+ grafted neurons or 
EGFP-negative host neurons (Fig. 4 J and K; fig. S 6 G). These data demonstrate the development 
of putative inhibitory synaptic contacts.    
Syngeneic pigs receiving spinal iPSCs-NSCs grafts show no humoral immunity 
against grafted cells at 3 months after cell transplantation 
To test for the presence of circulating anti-iPSCs-NPCs antibodies in syngeneic pigs 
grafted spinally with iPSCs-NPCs, a combined in vivo and ex vivo immunostaining assay was 
developed. First, a homogenate mixture composed of proliferating or induced iPSCs-NPCs (in 
Freund’s adjuvant; non-EGFP-tagged cells) was injected subcutaneously to immunize an 
allogeneic pig (Fig. 5 A). In parallel, the same NPCs population (but expressing EGFP under SYN 
promoter) was injected into the striata or lumbar spinal cord in immunodeficient rats. Six months 
after grafting, rat brain and spinal cord sections containing iPSCs-NPCs-EGFP were harvested and 
stained using the sera taken from immunized pig (positive control), naive non-immunized 
allogeneic pig (negative control) and syngeneic pigs that had previously received spinal iPSCs-
NPCs-EGFP grafts. 
Staining of rat striatal and spinal cord sections (harvested at 6 months post-grafting) 
containing iPSCs-NPCs-EGFP+ grafts with pig sera from immunized pigs showed cellular 
staining in grafted EGFP+ neurons (positive control, Fig. 5 B). No staining was observed with sera 
taken from non-immunized pigs (negative control) or from a syngeneic pig grafted spinally with 
iPSCs-NPCs-EGFP (Fig. 5, C and D). These data demonstrate that no humoral immune reaction 
developed in syngeneic pig for a minimum of 3 months after cell grafting. 
Short-term immunosuppression (4 weeks) induces immune tolerance to allogeneic 
iPSCs-NPCs grafted spinally in adult pigs with previous chronic spinal traumatic injury 
We next tested if porcine iPSCs-NPCs (the same cell line as used for syngeneic spinal 
grafting) could survive and differentiate after transplantation into the lumbar spinal cord of 
allogeneic pigs in the context of both spinal cord injury and transient (1 month)  
immunosuppression. Allogeneic minipigs (n=3) that had undergone a  spinal cord injury in the L3 
segment received 20 bilateral grafts of iPSCs-NPCs-EGFP (under ubiquitin (UBI) promoter; 
50,000 live cells/µl, 10 µl/injection)  2.5 months after spinal trauma. After cell grafting animals 
were immunosuppressed for 4 weeks with Prograf (0.025 mg/kg/day; iv). After an additional 2.5 
months without immunosuppression, the presence of grafted cells was analyzed in spinal cord 
sections using immunofluorescence (Fig.6A). The relative number (% of total EGFP+ neurons, 
astrocytes and oligodendrocytes) of double-immunoreactive EGFP/DCX, EGFP/NeuN, 
EGFP/NSE neurons and EGFP/GFAP and EGFP/OLIG2 glial cells was quantified using 4 
sections/animal containing a clearly identifiable EGFP+ graft. The degree of SLA mismatch 
between the iPSCs-NPCs donor and graft recipients was analyzed in skin fibroblast DNA extracts 
using PCR-based SLA genotyping assays (14, 15). 
The injured spinal cord regions were found to be extensively populated by grafted NPCs-
EGFP+ cells in all 3 animals. The length of individual fused grafts ranged between 2-3 cm (Fig. 6 
B, C; fig. S 7 A). Staining with NeuN antibody showed NeuN+ neurons throughout the EGFP+ 
grafts (Fig. 6 B, D-F). A high density of SYN expression in EGFP+ grafts was also observed and 
was similar to that seen in the surrounding host tissue (Fig. 6 B; top right insert). Co-staining 
with NeuN and NF antibody showed a high density NF+ neurites in NeuN populated grafts (Fig. 
6 G). Staining with DCX and NSE antibody showed numerous DCX/NSE-expressing EGFP+ 
neurons at different stages of neuronal maturation (Fig. 6 H; fig. 7 S B-E). Triple staining with 
SYN, EGFP and VGAT antibodies confirmed a high density of SYN/VGAT terminals associated 
with EGFP puncta (Fig. 6 I; fig. S 7F). EGFP/SYN/VGAT+ puncta were opposed to a 
postsynaptic gephyrin+ puncta seen on EGFP+ grafted neurons or EGFP-negative host neurons 
(Fig. 6J; fig. S 7G). Staining with postsynaptic excitatory marker Homer 1 (postsynaptic protein 
associated with group 1 metabotropic glutamate receptor) showed a clear punctate-like staining on 
neuronal soma and axons of EGFP+ grafted neurons (Fig. 6 K; fig. S 7 H). 
Staining with GFAP and OLIG2 antibodies revealed graft-derived astrocytes and 
oligodendrocytes (Fig. 6 L-N; fig. S 7I). Co-staining with choline acetyltransferase (CHAT) 
antibody showed the occasional presence of CHAT+  neurons (fig. S 7J).  Detailed regional 
analysis of NeuN expression in UBI-EGFP-grafted regions showed homogenous distribution of 
NeuN+ neurons through the whole engrafted region (fig. S 8 A-D). A quantitative analysis (% of 
total EGFP+ neurons) of double-immunoreactive EGFP/DCX, EGFP/NeuN, EGFP/NSE, 
EGFP/GFAP and EGFP/OLIG2 neurons and glial cells is presented in Table S 1.  
The H&E staining showed well-incorporated individual grafts with morphology consistent 
with mature neural tissue (fig. S 9A).  In comparison with the host surrounding tissue, incomplete 
myelinization was observed, as evidenced by a low density of MBP immunoreactivity within 
EGFP+ grafts (fig. S 9, B and C). Numerous triple-stained EGFP/VIMENTIN/Ki67+ cells were 
found within EGFP+ grafts (fig. S 9D-insets, E). These data suggest ongoing myelinization and 
proliferation of glial precursors. To study the dynamics of cell proliferation (Ki67+ cells) in 
developing porcine spinal cord, we next stained spinal cord sections prepared from 70-days-old 
porcine fetus (gestational period in pig is around 115 days), newborn piglet  and adult naive pig 
(18 months old). In the 70-day-old fetus a high density of Ki67+ cells in both white and gray matter 
regions was seen. The number of Ki67+ cells decreased in newborn piglets but was still present in 
the adult pig (fig. S 9 F-I). These data are consistent with a previous report in mice which 
demonstrated an ongoing proliferation of glial precursors in the intact adult spinal cord (16).  
 
Transiently-immunosuppressed (4 weeks) allogeneic, spinally-injured  pigs show no 
humoral or cellular immunity against grafted iPSCs-NPCs at 2.5 months after cell 
transplantation 
Next, we tested the presence of circulating antibodies against iPSCs-NPCs by staining 
mature (6 months post-grafting) iPSCs-NPCs grafts in the rat striata with sera harvested from 
allogeneic iPSCs-NPCs-grafted pigs. In contrast to the strong staining observed with sera from 
anti-iPSCs-NPCs-immunized pig, no staining was detected with sera from allogeneic graft 
recipients (Fig. 6, O and P). As shown in Table S 4, A and B, the SLA genotypes of the iPSCs-
NPCs donor and the allogeneic graft recipients were well mismatched at both the antigen (allele-
group) and allele level across the class I (SLA-1, SLA-2, SLA-3) and class II (DRB1, DQA, DQB1) 
loci tested (17-23).  
To further probe for the presence of an immune response in cell-grafted spinal cord regions, 
spinal sections were stained with porcine-specific anti- major histocompatibility complex II 
(MHC-II), CD45 (leukocyte common antigen), CD8 (co-receptor for the T cell receptor) and 
ionized calcium-binding adapter molecule 1 (Iba1; microglial marker) antibodies. Sections were 
taken from: i) spinal cord of syngeneic pigs 3 months after iPSCs-NPCs grafting without 
immunosuppression, ii) spinal cord of injured, continuously-immunosuppressed allogeneic pigs 4 
weeks after iPSCs-NPCs grafting, and iii) spinal cord of injured, transiently-immunosuppressed 
allogeneic pigs 3.5 months after iPSCs-NPCs grafting. In syngeneic pigs the staining with anti-
MHC-II antibody showed that the immunoreactivity was restricted around the needle injection 
tracts (Fig. 7A). In allogeneic spinally-injured animals with continuous or transient 
immunosuppression a more diffuse staining pattern was seen and MHC-II+ cells were observed 
throughout the EGFP+ graft as well as in surrounding injured host tissue (Fig. 7, B and C). 
Staining with Iba1 antibody exhibited a very similar staining pattern as was seen for MHC-II 
staining (Fig. 7 D-F). Staining with CD45 and CD8 antibody showed accumulation of both cell 
types around the cell injection tract in syngeneic pigs and more diffuse presence of CD45/CD8-
positive cells in allogeneic spinally-injured pigs with continuous or transient immunosuppression 
(Fig. 7 G-I). Analysis of double MHC-II and Iba1-stained sections showed that virtually all MHC-
II+ cells expressed Iba1 (Fig. 7J).  Quantitative comparative analysis of CD45 and CD8 positive 
cells between allogeneic spinally-injured continuously-immunosuppressed animals (1-month post-
grafting survival) and animals with transient immunosuppression 3 months after grafting showed 
a significant decrease in the number of both CD45+ and CD8+ cells  3 months after cell grafting 
in transiently immunosuppressed animals (Fig. 7, K and L).  
These data demonstrate that spinal grafting of iPSCs-NPCs in syngeneic non-immune-
suppressed or allogeneic transiently-immunosuppressed animals leads to a robust graft survival 
with minimal immune response at the site of cell grafting.  
Analysis of neurological function in allogeneic NPC-grafted animals 3.5 months after 
grafting was performed using a previously developed porcine neurological scale designed to 
quantify the loss of motor function after spinal cord traumatic injury in adult pigs (24). Grade “0” 
corresponds with complete paraplegia with no detectable movement in the hind limbs and grade 
“14” corresponds with normal ambulatory function. NPCs-grafted animals showed 2-3 degrees 
improvement (from grade 6 to grade 8 or 9) compared to pre-transplantation baseline. This 
corresponds to better movement in all three joints of lower extremities but with no ability to  
support weight or walk. 
Reprogramming factors and immunogenic genes are not expressed in vivo in grafted 
iPSCs-NPCs 
We next studied the residual protein expression of reprogramming factors (OCT4, KLF4 
and SOX2) and Sendai virus-associated protein (SeV) in grafted cells at 3 and 7 months post-
grafting by using sections taken from grafted rat striata and allogeneic pig spinal cord. Sections 
were also stained with Ki67 antibody. Staining with OCT4 and KLF4 antibody showed no residual 
staining in grafted cells (fig. S 10A-H). Staining with SOX2 antibody showed regularly distributed 
SOX2+ cells within EGFP+ grafts in both rat striata and allogeneic pig spinal cord (fig. S 10 I-L). 
In allogeneic pig spinal cord a specific SOX2 expression was also seen in endogenous ependymal 
cells of central canal (fig. S 10L; white dotted line). Staining with Ki67 antibody showed regularly 
distributed double EGFP/Ki67-stained cells in both rat striata and allogeneic pig spinal cord grafts. 
(fig. S 10 M-P). Staining with anti-SeV antibody revealed only occasional presence of Sendai 
virus-associated protein in grafted EGFP+ cells (fig. S 11 A-D). The mRNA sequencing analysis 
showed no apparent differences in several immunogenic genes including Hormad 1 and Cyp39A1 




Using non-integrating Sendai virus (encoding OCT4, SOX2, KLF4 and c-MYC) we 
demonstrated the successful reprogramming of porcine skin fibroblasts harvested from adult fully 
SLA-matched pigs to iPSCs. After iPSCs induction,  we isolated the NPCs by manual selection 
and expanded for more than 20 passages while maintaining a stable karyotype and expressing 
markers typical of NPCs (such as SOX1, SOX2, NESTIN and PAX6). Once grafted into the striata 
of immunodeficient rats or the spinal cord of syngeneic naive-non-injured pigs in the absence of 
immunosuppression, NPCs differentiated into functional neurons and glial cells (astrocytes, 
oligodendrocytes). Consistent with an advanced stage of grafted NPCs maturation, the mRNA 
sequencing analysis of porcine-specific transcripts in rat striata at 10 months post-grafting showed 
a pattern of expression similar to control mature pig CNS tissue. Moreover,  long-term survival of 
iPSCs-NPCs-derived cells was observed after grafting into spinal cord-injured allogeneic pigs that 
had received only transient immunosuppression.  
Previous study have reported immunogenicity from syngeneic mouse iPSCs upon 
transplantation that may be related to an ongoing overexpression of pluripotent genes (25). In 
addition, several other factors such as expression of virus-related proteins generated by episomal 
vectors used for reprogramming and the MHC expression in specific iPSC-cell derivatives may 
contribute to overall immunogenicity of transplanted cells (25). We have addressed those issues 
and have demonstrated that i) there is no expression of pluripotent genes at 3-7 months post-
transplantation, and ii) only occasional Sendai virus-associated protein was present in grafted 
iPSCs-NPCs. These data suggest that, although a residual Sendai viral protein is present at the 
moment of grafting, it is not sufficient to trigger hyper-acute or late T-cell mediated rejection. We 
have also demonstrated a lack of humoral or cellular response in syngeneic and allogeneic pigs 
receiving iPSCs-NPCs grafts. These data further demonstrate that even a mature iPSCs-NPCs graft 
does not express antigens which would be sufficient to initiate an immune response at prolonged 
periods after grafting. 
In addition, there are several other variables which we believe need to be considered while 
generating iPSCs-derived transplantable cell lines for experimental or clinical application. It has 
been demonstrated that several genes are expressed at abnormally high levels in mouse iPSCs. A 
subset of upregulated genes with known immunogenic properties, including Hormad1, Zg16 and 
Cyp3a11, has been found to be directly linked to the T-cell mediated rejection of teratomas that 
formed after grafting of mouse iPS cell lines into syngeneic recipients (25). All the iPSCs used in 
this previous study (13) came from fetal fibroblasts, an unlikely source for future therapies in 
humans, and the gene expression changes may be related to epigenetic memory of this specific 
developmental time. The use of adult fibroblast  in our current experiments  may contribute to the 
lack of immunogenic gene upregulation. 
Altered gene expression can be also due to the transcriptional memory observed in iPSCs 
(26, 27) or caused by somatic alterations in protein-coding regions accumulated in these cells (28). 
Whether there is increased activity of potentially immunogenic proteins in long-term expanded 
iPSCs-derived cell lines is not defined at present. Thus a periodic analysis of such changes needs 
to be performed to assure consistency of the genetic profile across specific lots of transplantable 
cells.  
We have previously demonstrated that culturing human ES cells in the presence of animal 
components, such as mouse feeder cells or bovine albumin, leads to the incorporation of animal 
molecules in the membranes of human cells (29). These molecules, such as N-glycolylneuraminic 
acid (Neu5Gc), contaminated human ES cells and initiated an antibody-mediated complement 
deposition when the cells were exposed to human sera. Accordingly, in our current study, to avoid 
the contamination of generated iPSCs by non-porcine animal component(s) we have used porcine 
fetal skin-derived fibroblasts as a feeder layer and no serum derived from other animal species was 
used.  Thus, the derived iPSCs-NPCs had no non-porcine elements in their membranes that can 
elicit an immune reaction in the syngeneic or allogeneic graft recipients.  
Previous studies reported the transplantation of iPSCs-derived dopaminergic precursors 
using intrastriatal autologous or allogeneic grafting in non-human primates without 
immunosuppression (30, 31). Minimal or no immune response was seen in autologous grafts while 
a progressive acquired immune response was seen in allogeneic graft recipients at 3.5-4 months 
after cell grafting. We show that the transient immunosuppression protocol used in our current 
study is effective in inducing a long-term graft tolerance in allogeneic spinally-injured and SLA-
mismatched recipients. These results are similar to our previously reported data which demonstrate 
tolerance across a two-haplotype, fully MHC-mismatched barrier in miniature swine renal 
allografts after transient (12 days) high-dose treatment with tacrolimus (32). More recently, a 
functional engraftment of allogeneic iPSCs-derived cardiomyocytes after a direct intra-myocardial 
injection in the cynomolgus monkey model of myocardial infarction was reported. In this 
experiment, continuous immunosuppression with tacrolimus was used (33). Other groups have 
reported on functional benefit after spinal grafting of human iPSCs-NPCs in mouse and marmoset 
spinal injury models (34, 35)   and also demonstrated low immunogenicity of mouse iPSCs-derived 
NPCs (36, 37).  
Since the spinal cord and brain represent sites of immune privilege, it has long been 
speculated that only transient immune suppression is sufficient to ensure long-term engraftment of 
human fetal tissue-derived or iPSCs-derived NPCs in human allogeneic graft recipients. Thus, our 
findings demonstrate in a large animal model of spinal cord traumatic injury that in fact a transient 
4-week immunosuppression is effective in inducing immune tolerance against allogeneic iPSCs-
NPCs grafts. One limitation of our current study is that a relatively short post-grafting period of 
survival was used in pig component of the study. Accordingly, a prolonged postgrafting survival 
likely exceeding 1 year will be needed to confirm a permanent iPSCs-NPCs engraftment once cells 
are grafted into syngeneic or allogeneic transiently-immunosuppressed recipients. 
Our pre-clinical large animal model system will allow us to establish prospective assays to 
predict graft rejection in the context of autologous, syngeneic or allogeneic grafting of iPSCs-
derived neural precursors in naive or previously-injured spinal cord. Similar to the studies from 
Zhao et al. (25), we expect that a profiling of gene regulation, membrane-bound and soluble-
releasable proteins that have immunogenic properties, and recipient T-cell activation assays, will 
be important in determining the immunogenicity of prospective iPSCs-derived lineage-committed 
cell lines to be used for in vivo grafting. In this manner, the degree of immune suppression could 
be personalized to the quantity of recipient T cell reactivity to graft antigens, thereby ensuring that 
appropriate immune suppression is used.  
 
  
MATERIAL and METHODS 
Study design 
This study was designed to characterize the survival of porcine iPSCs-NPCs after spinal grafting in 
adult naive syngeneic (non-immunosuppressed) or chronic spinally-injured allogeneic (transiently 
immunosuppressed) pigs.  To generate pluripotent cells,  we used sendai virus encoding 4 reprogramming 
factors to reprogram adult pig fibroblasts (harvested from inbred SLA-matched pigs) in vitro. Pluripotent 
nature of established iPSCs colonies was determined by in vitro induction into all 3 germ layers (ectoderm, 
mesoderm, endoderm) and by the formation of in vivo teratoma. NPCs were then induced from pluripotent 
colonies using NSC-induction protocol and established NPCs characterized in vitro and in vivo by: i) 
expression of NPCs markers (flow cytometry or indirect immunofluorescence, ii) ability of neurons to 
spontaneously depolarize after long-term in vitro induction (Ca2+ oscillation),  and iii) ability of iPS-
derived neurons to generate action potential in ex-vivo striatal slices. To study a multipotent potential of 
established iPSCs-NPCs cells (SYN-EGFP) grafted into rat striata, we used  immunofluorescence staining 
using neuronal and glial markers and mRNA sequencing using bioinformatics protocol which separates the 
pig mRNA sequence reads from the host rat mRNA reads. Neurotransmitter phenotype of grafted iPSCs-
NPCs-derived neurons was studied in EGFP+ grafts in rat striata and pig spinal cord by 
immunofluorescence staining with pre- and post-synaptic markers specific for inhibitory or excitatory  
neuronal phenotype.  
For quantitative analysis of immune response markers (CD45 and CD8) spinal cord sections taken 
from iPSCs-NPC-grafted: i) syngeneic pigs, ii) allogeneic pigs at the end of 4 weeks immunosuppression, 
and iii) allogeneic pigs at 2.5 months after immunosuppression was terminated, were used. The presence 
of positively-stained CD45 and CD8 cells was analyzed separately in the EGFP+ grafts and in surrounding 
host tissue.  
Full details on the methods of in vitro iPSCs and iPSCs-NPCs generation/characterization and in 
vivo iPSCs-NPCs grafting and post-mortem analysis can be found in the Supplementary Materials. 
 
Statistical analysis 
For statistical analysis the number of positively-stained (CD45+ and CD8+)  cells in allogeneic 
animals (pigs) with continuous and transient immunosuppression was compared using unpaired, two-
tailed Student’s T-test for single comparisons. Data were considered significantly different if P < 0.05. 
GraphPad Prism software was used to run Student’s tests.  
 
 
 Supplementary Materials 
Supplementary Methods 
 
fig.S1. Porcine fibroblasts-derived iPS generate ectoderm, mesoderm and endoderm cell derivatives in 
vitro and in vivo.   
fig.S2. Previously frozen, in vitro expanded porcine iPSCs-derived NPCs show stable karyotype and 
generate neural derivatives (neurons, astrocytes and oligodendrocytes) after in vitro induction.  
fig.S3. Long-term grafted (7-10 months) porcine iPSCs-NPCs in rat striata show maturation protein- 
and mRNA signature which is consistent with mature porcine CNS tissue. 
fig.S4. Porcine iPSCs-NPCs grafted into rat striata show no tumor formation and incomplete 
myelinization at 7 months postgrafting. 
fig.S5. Porcine iPSCs-NPCs –EGFP+ grafts in rat striata show normal vascularization and no changes 
in tumor suppressors or proto-oncogenes at 7-10 months post-grafting. 
fig.S6. iPSCs-NPCs grafted into syngeneic pig spinal cord in the absence of immunosuppression show 
long-term survival and neuronal and glial differentiation at 3 months after transplantation. 
fig.S7. iPSCs-NPCs grafted spinally in allogeneic, transiently-immunosuppressed (1 month 
immunosuppression) pigs with previous spinal traumatic injury show neuronal and glial differentiation 
at 3.5 months after grafting. 
fig.S8. Spinally-grafted iPSCs-NPCs in allogeneic, spinally-injured pig with transient 
immunosuppression (1 month) show extensive neuronal (NeuN) differentiation at 3.5 months after 
grafting.  
fig.S9. iPSCs-NPCs grafted spinally in allogeneic pig  with previous spinal injury don’t form tumors 
and show incomplete myelination at 3.5 months postgrafting. 
fig.S10. Reprogramming factors (OCT4, KLF4) are silenced in mature iPSCs-NPCs grafts in rat striata 
or spinal cord in allogeneic pig with previous spinal traumatic injury. 
fig.S11. Long-term grafted  iPSCs-NPCs in rat striata or spinal cord of allogeneic pig show only 
occasional presence of Sendai virus-associated protein in grafted cells and show no change in 




 Table S 1. Quantitative analysis of neuronal and glial differentiation in EGFP grafts. 
Table S 2. Electrophysiological properties of three transplanted iPSC neurons into the striatum of a 
rat at 8 months post-grafting. 
Table S 3. mRNA sequencing species sorting quantification. 
Table S 4A. SLA haplotypes of donor iPSCs-NPCs and allogeneic graft recipients. 
Table S 4B. Expected high-resolution (Hp) SLA typing and haplotype. 
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Figure 1.  In vitro-differentiated porcine iPSCs-derived neural precursors give rise to functional 
neurons. (A) Schematic diagram of the experimental time line and design in vitro and in vivo. (B-H) 
Cultured fibroblasts (B) formed colonies of pluripotent cells (Pluri. Colonies) at 10 days after infection 
(C, D) and expressed pluripotent markers including KLF4 (E), SOX2 (F), OCT4 (G) and Nanog (H).  
(I) Established iPSCs-derived embryoid bodies cultured in non-attachment culture flasks. (J) 
Hematoxylin and Eosin staining of mouse testes at 6 weeks after injection of iPS cells suspended in 
matrigel. Development of mature teratoma with identifiable all 3 germ layer derivatives including 
neural tube rosettes (1. ectoderm-red arrows; upper insert), smooth muscle (2. mesoderm-red arrows; 
middle insert) and gut cuboidal epithelium with goblet cells (3. endoderm-red arrows; lower insert) can 
be seen. (K, L) NPCs colonies were manually harvested from the periphery of attached and induced 
embryoid bodies/neural rosettes (K) and further expanded (L). (M-P) Long-term expanded NPCs show 
expression of markers typical of neural precursors including SOX2 (M), PAX6 (N, P), SOX1 (O) and 
Nestin (N,O). (R-U) Staining of induced SYN-EGFP-NPCs (R) with neuronal markers DCX (S, T), 
NeuN (S) and Tuj1 (U) was seen. A sub-population of DCX+ neurons was GABA-immunoreactive (T). 
(V) Fluo-4 AM-loaded, two month-induced NPCs showing spontaneous intracellular calcium 
oscillation in axons (1, 1’) and neuronal soma (2, 2’ and 3, 3’). Scale bars: J-500 µm; M-10 µm; N-15 
µm; O-10 µm; S, T, U-10 µm). 
Figure 2. Intrastriatal grafting of iPSCs-NPCs in immunodeficient rats is associated with robust 
neuronal differentiation and appearance of mature and functional grafted neurons at 7-10 
months after grafting. (A, B) Schematic representation of the experimental time line and design. (C, 
D) Action potential firing (C) (evoked by a depolarizing step of current of 75 pA for 500 ms from 
resting potential in current-clamp at 0 pA), and voltage gated sodium and potassium currents (D) 
(evoked by a series of depolarizing steps of 5 mV in voltage-clamp at -70 mV) in grafted SYN-EGFP 
neurons. (E, F) Staining of paraformaldehyde-fixed SYN-EGFP+ grafted striatal section with NeuN 
(E) and NSE (F) antibodies. (G-I) Immunofluorescence staining with SYN, NeuN, VGAT and gephyrin 
antibody (I) in the core of EGFP+ graft (G, I) and in areas distant from the graft core (medial region of 
NPCs-grafted striatum), (H). (Scale Bars: E- 50 µm; F- 10 µm; G-5 µm; H, I-20 µm). 
Figure 3. iPSCs-NPCs grafted into striata of immunodeficient rats acquire genetic signature 
of mature porcine CNS at 10 months after grafting.  (A-D) Schematic representation of the 
experimental time line and design. (E) Analysis and pre-processing of mixed-species RNA-seq 
reads. (F) t-distributed stochastic neighbor embedding (t-SNE) plot showing the degree of 
correlation in gene expression profiles between the indicated samples. 
Figure 4. Spinally-grafted iPSCs-NPCs show long-term survival and neuronal and glial 
differentiation in syngeneic recipient in the absence of immunosuppression.  
 (A) Immunofluorescence staining showing EGFP fluorescence in the core of the graft.  (B, C) 
Immunofluorescence staining showing NF and GFAP-stained processes in the same areas as in “A”. 
(D-F) Staining with DCX  (D) NeuN (E) and NSE (F) in EGFP+ grafts. (G-I) Immunofluorescence 
staining showing EGFP/NF+ neurites, in areas cranial and caudal to the borders of the graft. (J, K) Co-
staining of SYN-EGFP+ grafts with VGAT and gephyrin (Gephr) antibodies in the core of the graft. 
(Scale Bars: A-30 µm; B-125 µm; C-10 µm; D-40 µm; E, F-35 µm; G, H, I-50 µm; J, K-20 µm). 
  
Figure 5. Syngeneic iPSCs-NPCs recipients show no humoral immunity against grafted cells at 3 
months after cell transplantation in the absence of immunosuppression. 
 (A) Schematic diagram of the development of in vivo/ex vivo staining protocol to detect the presence 
of circulating antibodies against grafted iPSCs-NPCs. (B-D) Staining of mature iPSCs-NPCs grafts in 
rat striatum and rat spinal cord with serum from previously anti-iPSCs-NPCs-immunized pig (B), sera 
harvested from naive non-immunized pig (C) or with sera from syngeneic iPSCs-NPCs-grafted pigs 
(n=3)  (D) 3 months after grafting. (Scale Bars: B, C, D-40 µm). 
 
Figure 6. Spinally-grafted iPSCs-NPCs show long-term survival and neuronal and glial 
differentiation in allogeneic spinally-injured pigs with transient immunosuppression. (A) 
Schematic diagram of experimental design. (B-F) Co-staining of EGFP+ grafts  with NeuN, 
synaptophysin and GFAP antibodies. (G) Co-staining with NF and NeuN antibodies in the core of the 
graft.  (H) Co-staining of DCX, EGFP and NSE in the core of the graft. (I) Confocal microscopy image 
of SYN, VGAT puncta on EGFP+ grafted neurons. (J) Staining of EGFP+ grafted neuron with VGAT 
and Gephr antibody. (K) Co-staining with HOMER and NF antibodies of EGFP+ grafted neurons 
(white arrows indicate HOMER+ puncta on neuronal soma or axons of EGFP+ neurons). (L-N) 
Confocal images of double-labeled EGFP+/OLIG2+ oligodendrocytes and EGFP+/GFAP+ astrocytes. 
(O, P) Staining of mature iPSCs-NPCs-EGFP+ grafts in rat striata with sera from anti-iPSCs-NPCs-
immunized pigs (O) or with sera from iPSCs-NPCs grafted-transiently-immunosuppressed allogeneic 
pig (n=3) (P). (Scale Bars: B-300 µm; C-500 µm; D, E, F-60 µm; G-250 µm; H-60 µm; I-10 µm; J-5 
µm; K- 10 µm; L, N-10 µm; O, P-40 µm). 
Figure 7. Transient immunosuppression (4 weeks) supports long-term graft survival and is 
associated with progressive decrease in spinal regional inflammatory response in iPSCs-NPCs-
grafted spinally-injured allogeneic pig.  (A-C) Immunofluorescence staining for MHC-II and EGFP 
around cell injection needle tract in syngeneic pigs (A; n=3) and in allogeneic continuously-
immunosuppressed (B; n=3) or transiently immunosuppressed (C; n=3) spinally-injured pigs 4 weeks 
or 3.5 months after cell grafting. (D-F) Immunofluorescence staining for Iba-1 and EGFP around cell 
injection needle tract in syngeneic pigs (D) and in allogeneic continuously-immunosuppressed (E) or 
transiently immunosuppressed (F) spinally-injured pigs 4 weeks or 3.5 months after cell grafting. (G-
I) Immunofluorescence staining for CD45, CD8 and EGFP around cell injection needle tract in 
syngeneic pigs (G) and in allogeneic continuously-immunosuppressed (H) or transiently 
immunosuppressed (I) spinally-injured pigs 4 weeks or 3.5 months after cell grafting.  (J) 
Colocalization of MHC-II with  Iba-1 in the core of the graft. (K, L) Quantitative analysis of CD45+ 
and CD8+ leukocytes in EGFP+ grafts and in surrounding host tissue  (Student’s T-test; * P < 0.05) 
(Scale Bars: A, B, C, G, H, I-300 µm; D, E, F-20 µm; J-10 µm). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
 
  
 
 
 
 
 
 
 
 
  
